Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
Pooled result · Non-adherence (PDC <80%)Result — go to the resultRelative risk 0.86 95% CI 0.72–1.02Authors' conclusion
In this meta-analysis of eight studies that included approximately 200 000 patients, there was no difference in adherence to SGLT2is versus GLP-1RAs. However, SGLT2i use was associated with higher adherence when the analysis was limited to US studies.
Study context
- Population
- Adults in real-world studies directly comparing adherence to SGLT2is vs GLP-1RAs, measured by proportion of days covered; Medline and Embase through October 2023
- Participants
- 205,103 adults8 studies
- Comparison
- SGLT2i vs GLP-1 RA
- Outcome
- Non-adherence: proportion of patients with PDC <80%
Methodological detailssubgroup analysis of US studies
- Subgroup analysis of US studies
Pooled result
Non-adherence (PDC <80%)
Relative risk
0.86
95% CI 0.72–1.02
SGLT2isvs GLP-1RAs
RR 0.86 (95% CI 0.72–1.02)
As reported in the abstract
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Non-adherence (PDC <80%), subgroup: US studies only23% lower risk of non-adherence with SGLT2i | 0.77 (0.72–0.82) | |
| 0.512Relative risk (log scale) |
- Non-adherence (proportion of days covered (PDC) <80%), subgroup: US studies only: 5 US studies
Original publication
Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis. Diabetes Obes Metab. Published 23 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →